Table 4.
Patients with grade 3–5 non-hematologic adverse events within 100 days of autologous stem cell transplantation regardless of attribution. (Supplemental)
| Adverse event | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|
| Allergy/Immunology | 2 (6) | - | - |
| Cardiac General | 2 (6) | - | - |
| Constitutional Symptoms | 1 (3) | - | - |
| Dermatology/Skin | 2 (6) | - | - |
| Gastrointestinal | 10 (28) | - | - |
| Genitourinary | 1 (3) | - | 1 (3)* |
| Hemorrhage | 6 (17) | - | - |
| Hepatic | - | - | - |
| Infection/Febrile neutropenia | 16 (44) | - | - |
| Lymphatics | 1 (3) | - | - |
| Metabolic/Laboratory | 9 (24) | 1 (3) | - |
| Musculoskeletal | 1 (3) | - | - |
| Neurologic | 1 (3) | 1 (3) | - |
| Pain | 3 (8) | - | - |
| Pulmonary | 4 (11) | 0 (0) | - |
| Secondary Malignancy | - | - | - |
| Vascular | 1 (3) | - | - |
| Any adverse event | 28 (78) | 2 (6) | 1 (3)* |
Values are numbers (percentages) of patients. Adverse events were graded according to the NCI CTCAE 3.0 scale.
*
Renal failure and death due to tumor progression.